A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Study acronym: BARICADE-DELAY
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 113 to 112
  2. Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 2 of 10 entries
    • Site details revised at 19 of 113 sites
  3. Site details revised at 4 of 113 sitesv22
  4. Study sites: 111 to 113v21
  5. Study sites: 110 to 111v20
  6. Site details revised at 1 of 110 sitesv19
  7. Trial sites expanded: 107 → 110 locationsv18
  8. Site details revised at 3 of 107 sitesv17
  9. Site details revised at 3 of 107 sitesv16
  10. Study sites: 106 to 107v15
  11. Study sites: 107 to 106v14
  12. Site details revised at 26 of 107 sitesv13
  13. Study sites: 108 to 107v12
  14. Study sites: 107 to 108v11
  15. Site details revised at 3 of 107 sitesv10
  16. Site details revised at 4 of 107 sitesv9
  17. Site details revised at 6 of 107 sitesv8
  18. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2026 to Jan 12, 2026
    • Site details revised at 107 of 107 sites
    v7
  19. Site contacts updated at 1 of 107 sitesv6
  20. Study sites: 108 to 107v5
  21. Study sites: 107 to 108v4
  22. Study sites: 106 to 107v3
  23. Study sites: 107 to 106v2
  24. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
Diabetes
5,141 trials monitored
See 246 trials at risk
Type 1 Diabetes
895 trials monitored
See 42 trials at risk
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Trial Details
NCT Number NCT07222137
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Diabetes Mellitus, Type 1
Related terms Diabetes Mellitus, Type 1
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov